The FY2025 (Dec) proxy of Adaptive Biotechnologies names 19 peer companies for pay. Among Adaptive Biotechnologies and these peers, CEO pay was 4th highest of 5 and total shareholder return was the lowest of 5.
4th highest of 5in Adaptive Biotechnologies and its pay peers, FY2025 (Dec) by CEO pay:
5th highest of 5in Adaptive Biotechnologies and its pay peers, FY2025 (Dec) by total shareholder return:
Pay peer group, FY2025 (Dec) proxy
| Natera | ||
| Twist Bioscience | ||
| Immunocore Holdings | ||
| Veracyte | ||
| Allogene Therapeutics, Inc. | Not disclosed | Not disclosed |
| CareDx, Inc. | Not disclosed | Not disclosed |
| Castle Biosciences, Inc. | Not disclosed | Not disclosed |
| Codexis, Inc. | Not disclosed | Not disclosed |
| Fulgent Genetics, Inc. | Not disclosed | Not disclosed |
| Guardant Health | Not disclosed | Not disclosed |
| Maravai LifeSciences Holdings, Inc. | Not disclosed | Not disclosed |
| Mesa Laboratories, Inc. | Not disclosed | Not disclosed |
| Myriad Genetics, Inc. | Not disclosed | Not disclosed |
| NeoGenomics, Inc. | Not disclosed | Not disclosed |
| Pacific Biosciences of California, Inc. | Not disclosed | Not disclosed |
| Quanterix Corporation | Not disclosed | Not disclosed |
| Recursion Pharmaceuticals | Not disclosed | Not disclosed |
| Sage Therapeutics, Inc. | Not disclosed | Not disclosed |
| Voyager Therapeutics, Inc. | Not disclosed | Not disclosed |
PSU comparator group
The companies that relative total shareholder return is measured against for performance stock units.
| S&P Biotechnology Select Industry Index (index) | Not disclosed | Not disclosed |
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.